Can the HPV vaccine cause injury and/or death?
IMPORTANT NOTE: Corvelva invites you to get in-depth information by reading all the sections and links, as well as the manufacturer's product leaflets and technical data sheets, and to speak with one or more trusted professionals before deciding to vaccinate yourself or your child. This information is for informational purposes only and is not intended as medical advice.
The following article tries to shed light on the vast world of adverse reactions, with a specific look at the one against Papillomavirus, but we urge you to read all the focuses reported below to understand the other related issues, such as the problem of multiple vaccines, the hypersensitivity to one or more vaccine compounds, the SIDS problem and that of adjuvants. Most of the vaccines on the market are produced, for commercial purposes, in often multiple formulations and this makes the topic of vaccine damage much broader.
The problem of multiple vaccines (click to open)
The current vaccination calendars, especially for the pediatric age, provide for the administration of multiple antigens and vaccines in a single session, favoring comfort at the expense of safety. In order to be able to make a specific speech on the safety of vaccines, we must necessarily take into consideration the complexity of the phenomenon, advising all readers to adequately inform themselves on all aspects of vaccination, pros and cons.
Dr. Russell Blaylock, clinical assistant professor of neurosurgery at the University of Mississippi Medical Center, has studied "toxic synergy" for years and was able to observe that when two weakly toxic pesticides, where neither is able to cause Parkinson's syndrome in experimental animals, are combined with each other, can cause the disease even quickly and compares this phenomenon to that of multiple vaccines administered simultaneously: "Vaccinations, if too numerous and too close together, behave like a disease chronic".(a). Others Two studies have confirmed that sudden infant death can occur after inoculation of multiple vaccines in a single administration.(bc)
A study published in Human and Experimental Toxicology showed that countries that prescribe more vaccines in children tend to have higher infant mortality rates.(D) For example, in the United States, where children receive 26 vaccines, more than 6 children per 1000 live births die, while in Sweden and Japan, where 12 pediatric vaccines are administered, 3 deaths are reported for every 1000 live births. In the aforementioned study, the link between vaccines and SIDS is also considered.
From a Swiss study published in 2005 in the European Journal of Pediatrics(E) it results that, regarding the effects on preterm infants, the incidence of recurrent or increased apnea and bradycardia after administration of hexavalent vaccines is 13%. That same year, the same journal published a German study that had examined sudden infant deaths after hexavalent. The authors write: «These results, based on spontaneous reports, do not prove a causal relationship between vaccination and sudden infant death, but constitute a signal regarding one of the two available hexavalents; signal that should lead to intensify surveillance of sudden infant deaths after vaccination".(f)
In 2006, it was published in the medical journal Vaccine(g) the letter from a team of researchers from the University of Munich which reported «six cases of sudden infant death after hexavalent vaccination.. All found dead without explanation 1-2 days after vaccination». They had been classified as typical cases of sudden infant death but the autoptic verification had revealed neuropathological and histological abnormalities and all the children showed a significant cerebral edema which made them an exception compared to the other SIDS cases (Sudden Infant Death Syndrome). The researchers wrote that “Before the introduction of the hexavalent vaccine (in the years 1994-2000), we had observed the case of only one in 198 children with sudden infant death who died soon after the DTP vaccination. But between 2001 and 2004 they had identified five similar cases out of 74 with SIDS. That would indicate a thirteen-fold increase."
Also in 2006 on Virchows Archive(H), the team from the Institute of Pathology of the University of Milan wrote: «Experts from the European Agency for the Evaluation of Medical Products have analyzed the possibility that there could be a link between hexavalent vaccines and some cases of death. Participants included pathologists with experience in vaccines and sudden infant death syndrome who conducted the autopsies. But, as far as we know, little attention was paid to examination of the brainstem and blood heart on serial sections and there was no possibility of establishing a trigger role of the vaccine for these deaths. Here we report the case of a 3-month-old girl who died suddenly after hexavalent vaccination. Examination of the brain stem on serial sections revealed bilateral arcuate nucleus hypoplasia. The conduction system of the heart had persistent fetal dispersion and degeneration. This case offers a unique understanding of the possible role of the hexavalent vaccine in triggering a lethal consequence in a vulnerable child. Any case of sudden and unexpected death that occurs soon after birth or in early childhood, especially if following a vaccination, should always undergo a full necropsy, according to guidelines.
References
- Blaylock R, "Vaccinations: the hidden dangers", The Blaylock Wellness Report, May 2004, pp.1-9
- Ottaviani G. et al., "Sudden infant death syndrome (SIDS) shortly after hexavalent vaccination: another pathology in suspected SIDS?", Virchows Archiv., 2006, 448, pp. 100-104.
- Zinka B. et al., "Unexplained cases of sudden infant death shortly after hexavalent vaccination", Vaccine, July 2006, 24 (31-32), pp. 5779-5780.
- Miller NZ et al1. , "Infant mortality rates regressed against number of vaccine doses routinely given: there is a biochemical or synergistic toxicity?", Hum. Exp. Toxicol., May 2011.
- https://pubmed.ncbi.nlm.nih.gov/15843978/
- https://pubmed.ncbi.nlm.nih.gov/15602672/
- https://pubmed.ncbi.nlm.nih.gov/15908063/
- https://pubmed.ncbi.nlm.nih.gov/16231176/
The aluminum problem (click to open)
What is Aluminum?
Aluminum is a silvery-white light metal, malleable and resistant. These qualities make it useful in numerous industries and products, including machinery, construction, warehouses, cookware, kitchen utensils, textiles, dyes and cosmetics. Aluminum is also the most abundant metal in the earth's crust, and virtually all of the aluminum in the environment is found in the soil. However, aluminum is not found naturally in significant quantities in living organisms (such as plants and animals) and has no known biological function. Over the past century, the use of aluminum in some products has led to increased human exposure. The major sources of exposure are aluminum-containing foods (e.g., baking powder, processed foods, baby formulas, etc.), medical products (e.g., antiperspirants, antacids, etc.), allergy injections, and vaccines .1-3
Why is aluminum present in vaccines?
Some vaccines use aluminum compounds (aluminum hydroxide and aluminum phosphate) as adjuvants, which are ingredients that increase the immune response to an antigen (foreign substance).4-5 The US Food and Drug Administration (FDA) says that if some vaccines did not include aluminum, the immune response they trigger could decrease.6
Which vaccines contain aluminum?
The following vaccines contain aluminum and are given to infants, children and adolescents (Fig. 1):
- Hepatitis B (HepB)
- hexavalent
- Diphtheria, tetanus and pertussis (DTaP and Tdap)
- Haemophilus influenzae type b (PedvaxHIB)
- Pneumococcus (PCV)
- Hepatitis A (HepA)
- Papillomavirus virus (HPV)
- Meningococcus B (MenB)
Figure 1: Up to 18 doses of aluminum-containing vaccines are administered from birth to age 227-8
Is exposure to aluminum safe?
The FDA has considered aluminum generally recognized as safe (GRAS) since 1975.9 However, prior to 1990, there was no technology to accurately detect small amounts of aluminum administered to subjects in scientific studies.10 Consequently, the amount of aluminum that could be absorbed before the onset of adverse effects was not known.
Since the 1990s, thanks to technological advances, it has been observed that the small amounts of aluminum that remain in the human body interfere with a number of cellular and metabolic processes in the nervous system and tissues of other parts of the body.1-10-11 The greatest negative effects of aluminum have been observed in the nervous system and range from impaired motor skills to encephalopathy (altered mental status, personality changes, thinking difficulties, memory loss, seizures, coma and more).2-12
The United States Department of Health and Human Services (HHS) recognizes aluminum as a known neurotoxin.2 Additionally, the FDA has warned about the risks of aluminum toxicity in infants and children.13
FEDERAL REGISTER: The daily newspaper of the United States government"Even full-term infants with normal kidney function may be at risk due to rapid growth and immaturity of the brain and skeleton, as well as immaturity of the blood-brain barrier. Up to the age of 1 or 2, infants have a lower glomerular filtration rate than adults, which affects their kidney function. The agency fears that young children and those with immature kidney function are at increased risk of aluminum exposure. " |
How much oral aluminum is unsafe?
In 2008, the Agency for Toxic Substances and Disease Registry (ATSDR), a division of HHS, used studies on the neurotoxic effects of aluminum to determine that no more than 1 milligram (1.000 micrograms) of aluminum per kilogram of body weight per day to avoid the negative effects of aluminum.2
How much injected aluminum is unsafe?
To determine the amount of aluminum that can be safely injected it is necessary to convert the oral aluminum limit of the ATSDR. The ATSDR limit for oral aluminum (1.000 micrograms of aluminum per kilogram of body weight per day) is based on 0,1% of the oral aluminum that is absorbed into the bloodstream, as the digestive tract blocks almost all of the oral aluminum .2 In contrast, aluminum injected intramuscularly bypasses the digestive tract and 100% of the aluminum can be absorbed into the bloodstream over time (i.e., the proportion of aluminum absorbed is 1.000 times greater). To account for these different amounts of absorption, the oral aluminum limit of the ATSDR must be divided by 1000. This conversion leads to an ATSDR-derived blood aluminum limit of 1 microgram of aluminum (0,1% of 1.000 micrograms) per kilogram of body weight per day. Consequently, to avoid the neurotoxic effects of aluminum, no more than 1 microgram of aluminum per kilogram of body weight should enter the bloodstream on a daily basis. Figure 3 shows the ATSDR-derived blood aluminum limit for infants of various ages based on their weight.
How much aluminum is in vaccines?
The amount of aluminum in vaccines varies.16 In 1968, the US federal government set the limit for the amount of aluminum in vaccines at 850 micrograms per dose, based on the amount of aluminum needed to make some vaccines effective.6-17 Consequently, the amount of aluminum in aluminum-containing infant vaccines ranges from 125 to 850 micrograms per dose. Figure 4 shows the aluminum content of one dose of various vaccines given to children.
Have any studies compared the amount of aluminum in vaccines with the limit derived from the ATSDR (Agency for Toxic Substances and Disease Registry)?
In 2011, a study was published that aimed to compare the amount of aluminum in vaccines with the blood flow limit set by the ATSDR.18 However, this study incorrectly based its calculations on 0,78% oral aluminum absorbed into the bloodstream, rather than the 0,1% value used by the ATSDR in its calculations.19-20 As a result, the 2011 study hypothesized that nearly 8 times (0,78% / 0,1%) aluminum can safely enter the bloodstream, and this has led to an incorrect conclusion.
Is exposure to aluminum from vaccines safe?
Vaccines are injected intramuscularly, and the rate at which aluminum from vaccines migrates from human muscle into the bloodstream is unknown. Animal studies suggest that aluminum from vaccines can take anywhere from a couple of months to more than a year to enter the bloodstream, due to multiple variables.21-23 Since cumulative aluminum exposure from vaccines in children under one year of age exceeds the daily limit set by the ATSDR by several hundred (Fig. 3 and 4), the limit would still be exceeded if aluminum from vaccines entered the blood flow over the course of about a year. In addition, studies have shown that aluminum from vaccines is absorbed by immune cells and reaches parts of the body far from the injection site, including the brain.24
The extent of the adverse effects of aluminum in vaccines is not known, as safety studies have not been conducted comparing a population vaccinated with aluminum-containing vaccines with a population not vaccinated with such vaccines.
Aluminum limitation of blood flow derived from the ATSDR2-14-15
Figure 3: This graph shows the aluminum limit for children of various ages, as derived from the Toxic Substances and Disease Registry, a division of the United States Department of Health and Human Services. The limit indicates that no more than 1 microgram of aluminum per kilogram of body weight should enter the bloodstream on a daily basis to avoid the neurotoxic effects of aluminum.
Amount of aluminum in vaccines
References
- American Academy of Pediatrics, Committee on Nutrition. Aluminum toxicity in infants and children. Pediatrics. 1996 Mar; 97 (3): 413.
- Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for aluminum. Washington, DC: US Department of Health and Human Services; 2008.3, 13-24, 145, 171-7, 208.
- Yokel RA. Aluminum in food — the nature and contribution of food additives. In: El-Samragy Y, editor. Food additive. Rijeka (Croatia): InTech; 2012. 203-28.
- Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminum. Nat Rev Immunol. 2009 Apr; 9 (4): 287.
- Volk VK, Bunney WE. Diphtheria immunization with fluid toxoid and alum-precipitated toxoid. Am J Public Health Nations Health. 1942 Jul; 32 (7): 690-9.
- Baylor NW, Egan W, Richman P. Aluminum salts in vaccines — US perspective. Vaccine. 2002 May 31; 20 Suppl 3: S18-22.
- US Food and Drug Administration. Silver Spring (MD): US Food and Drug Administration. Vaccines licensed for use in the United States; [updated 2018 Feb 14; cited 2018 Feb 27]. https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/Ucm093833.htm.
- Centers for Disease Control and Prevention. Washington, DC: US Department of Health and Human Services. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2018. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf.
- US Food and Drug Administration. Silver Spring (MD): US Food and Drug Administration. SCOGS (Select Committee on GRAS Substances); [cited 2018 Aug 16]. https://www.accessdata.fda.gov/scripts/fdcc/?set=SCOGS.
- Priest ND. The biological behavior and bioavailability of aluminum in man, with special reference to studies employing aluminum-26 as a tracer: review and study update. J Environ Monit. 2004; 6: 376,392.
- Poole RL, Pieroni KP, Gaskari S, Dixon TK, Park KT, Kerner JA. Aluminum in pediatric parenteral nutrition products: measured versus labeled content. J Pediatr Pharmacol Ther. 2011; 16 (2): 92-7.
- Sedman A. Aluminum toxicity in childhood. Pediatr Nephrol. 1992 Jul; 6 (4): 383-93.
- US Food and Drug Administration, Department of Health and Human Services. Rules and regulations. Fed Regist. 2003 Jun; 68 (100): 34286.
- Centers for Disease Control and Prevention. Washington, DC: US Department of Health and Human Services. National Center for Health Statistics: Data table for boys length-for-age and weight-for-age charts; [cited 2019 April 2]. https://www.cdc.gov/growthcharts/who/boys_length_weight.htm.
- Centers for Disease Control and Prevention. Washington, DC: US Department of Health and Human Services. National Center for Health Statistics: Data table for girls length-for-age and weight-for-age charts; [cited 2019 April 2]. https://www.cdc.gov/growthcharts/who/girls_length_weight.htm.
- US Food and Drug Administration, Department of Health and Human Services. Revision of the requirements for constituent materials. Final rule. Fed Regist. 2011 Apr 13; 76 (71): 20513-8.
- Office of the Federal Register, National Archives and Records Service, General Services Administration. Rules and regulations. Fed Regist. 1968 Jan; 33 (6): 369.
- Mitkus RJ, King DB, Hess MA, Forshee RA, Walderhaug MO. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. Vaccine. 2011 Nov 28; 29 (51): 9538-43.
- Miller S, Physicians for Informed Consent. Erratum in 'Updated aluminum pharmacokinetics following infant exposures through diet and vaccination.' In: ResearchGate. Berlin (Germany): ResearchGate GmbH; 2020 Mar 6 [cited 2020 Mar 6]. https://www.researchgate.net/publication/51718934_Updated_Aluminum_pharmacokinetics_following_infant_exposures_through_diet_and_vaccines/comments.
- Physicians for Informed Consent. Newport Beach (CA): Physicians for Informed Consent. Erratum in 'Updated aluminum pharmacokinetics following infant exposures through diet and vaccination'; [cited 2020 Mar 6]. https://physiciansforinformedconsent.org/mitkus-2011-erratum/.
- Flarend RE, Hem SL, White JL, Elmore D, Suckow MA, Rudy AC, Dandashli EA. In vivo absorption of aluminum-containing vaccine adjuvants using 26Al. Vaccine 1997 Aug-Sept; 15 (12-13): 1314-8.
- Verdier F, Burnett R, Michelet-Habchi C, Moretto P, Fievet-Groyne F, Sauzeat E. Aluminum assay and evaluation of the local reaction at several time points after intramuscular administration of aluminum containing vaccines in the Cynomolgus monkey. Vaccine. 2005 Feb 3; 23 (11): 1359-67.
- Weisser K, Göen T, Oduro JD, Wangorsch G, Hanschmann KO, Keller-Stanislawski B. Aluminum in plasma and tissues after intramuscular injection of adjuvanted human vaccines in rats. Arch Toxicol. 2019 Oct; 93 (10): 2787-96.
- Masson JD, Crépeaux G, Authier FJ, Exley C, Gherardi RK. Critical analysis of reference studies on the toxicokinetics of aluminum-based adjuvants. J Inorg Biochem. 2018 Apr; 181: 87-95.
Article translated by Physicians for Informed Consent
The most commonly reported side effects of HPV vaccination include: injection site pain, swelling, and redness, nausea, headache, fever, fatigue, and muscle or joint pain. Fainting - termed a syncopal episode - following HPV vaccination has been reported frequently, and as a result, vaccine recipients are advised to remain seated or lie down to prevent syncope and potential injury that can result from a fall.(1)
Some of the adverse events reported by manufacturers during pre-licensing clinical trials include:
Gardasil - injection site pain, swelling, redness and bruising, fever, headache, nausea, dizziness, syncope, sometimes in conjunction with seizure-like activity, anaphylaxis, diarrhea, vomiting, cough, upper respiratory tract infection, nasal congestion , insomnia, malaise, oropharyngeal pain, nasopharyngitis, upper abdominal pain, gastroenteritis, appendicitis, pelvic inflammatory disease, urinary tract infection, pneumonia, pulmonary embolism, pyelonephritis, bronchospasm, and death.(2)
Cervarix - injection site pain, redness, bruising and swelling, syncope, fatigue, headache, gastrointestinal symptoms, rash, fever, arthralgia, myalgia, hives, urinary tract infection, back pain, dysmenorrhea, nasopharyngitis, influenza, vaginal infection , pharyngitis, chlamydial infection, arthritis, rheumatoid arthritis, celiac disease, diabetes mellitus, erythema nodosum, inflammatory bowel disease, hyperthyroidism, hypothyroidism, multiple sclerosis, transverse myelitis, systemic lupus erythematosus, thrombocytopenia, vasculitis, optic neuritis, vitiligo, and death.(3)
Gardasil 9 - injection site pain, swelling, redness, and bruising, syncope, fever, headache, nausea, dizziness, fatigue, diarrhea, upper respiratory tract infection, upper abdominal pain, oropharyngeal pain, myalgia, asthma attack, anaphylaxis, and death .(4)
Post-marketing adverse events reported for Gardasil 9 include: pulmonary embolism, idiopathic thrombocytopenic purpura, lymphadenopathy, autoimmune haemolytic anemia, pancreatitis, asthenia, chills, fatigue, malaise, bronchospasm, urticaria, anaphylaxis, acute disseminated encephalomyelitis, dizziness, transverse myelitis, Guillain-Barré syndrome, headache, motor neuron disease, paralysis, seizure, syncope (including syncope associated with other seizure-like activities and tonic-clonic movements) sometimes with fall injury, deep vein thrombosis, cellulitis, myalgia, arthralgia and death.
Over the past decade, there have been numerous studies and reports linking HPV vaccination to chronic disease in children and young adults. These include anaphylaxis,(5) lupus,(6-7) erythema multiforme,(8) acute disseminated encephalomyelitis,(9-10-11) transverse myelitis,(12) amyotrophic lateral sclerosis (ALS),(13) demyelination of the central nervous system,(14-15) multiple sclerosis,(16) including pediatric multiple sclerosis,(17) Guillain-Barre syndrome,(18-19) pancreatitis,(20-21) inflammatory bowel syndrome,(22) brachial plexus neuritis,(23) brachial neuritis,(24) optic neuritis,(25) neuromyelitis optica,(26) opsoclonus myoclonus,(27) vanishing white point syndrome,(28-29) acute cerebellar ataxia,(30) autoimmune hepatitis,(31) autoimmune neuromyotonia,(32) vasculitis,(33) thrombocytopenic purpura,(34) immune thrombocytopenic purpura,(35) postural orthostatic tachycardia syndrome (POTS),(36-37-38) complex regional pain syndrome (CRPS),(39) chronic fatigue syndrome (CFS),(40) and peripheral sympathetic nerve dysfunction.(41) A published questionnaire(42) on people who received HPV vaccination and looked at a combination of chronic diseases, including POTS, CRPS and fibromyalgia, found that 93% of people reporting symptoms related to these conditions were still unable to work or attend school four years later the vaccination. Additionally, several studies have linked HPV vaccination to primary ovarian failure, resulting in reduced fertility(43-44-45-46). A 2018 study found lower pregnancy rates in women who had received the HPV vaccination.(47)
Adverse events following HPV vaccination have also been linked to a relatively new medical condition called Adjuvant-Induced Autoimmune/Inflammatory Syndrome (ASIA).(48) In 2011, Dr. Yehuda Shoenfeld, founder and director of the Zabludowicz Center for Autoimmune Diseases in Israel, has released a paper associating four medical conditions - Gulf War Syndrome (GWS), macrophagic myofasciitis (MMF) syndrome (a syndrome previously related to use of aluminum adjuvants), siliconeosis (a condition related to silicone breast implants) and post-vaccination phenomena (chronic illness following vaccination) to previous exposure to adjuvants.
Dr. Shoenfeld noted that patients with these conditions had very similar clinical symptoms. Since then, published studies have linked the aluminum adjuvant in the HPV vaccine to several chronic health conditions, including postural tachycardia syndrome (POTS),(49) primary ovarian insufficiency (POF),(50) chronic epipharyngitis,(51) pseudo-neurological syndrome,(52) and severe somatoform and dysautonomic syndromes.(53) An epidemiological study of data collected by the Federal Vaccine Adverse Event Reporting System (VAERS) estimated that 3,6 per 100.000 doses of HPV vaccination resulted in symptoms consistent with a diagnosis of ASIA.(54)
A study on the effects of HPV vaccination found that both HPV antigens and aluminum adjuvant appear to have the ability to trigger autoimmune reactions and neuroinflammation in female mice, resulting in changes in behavioral patterns.(55)
Studies linking HPV vaccination to sudden death in previously healthy women have also been published. A study published in 2012 of two deaths following HPV vaccination concluded that the HPV-16L1 antigens present in HPV vaccines have the potential to cause fatal autoimmune vascular disease.(56) Also in 2012, Sin Hang Lee, a researcher and licensed pathologist, published a case study involving the sudden and unexplained death of a young woman six months after completing a three-dose series of Gardasil. Dr. Lee found HPV-16 gene DNA in blood and spleen similar to the HPV-16 gene DNA fragments contained in Gardasil. The DNA of the HPV-16 LI gene was bound to the same aluminum adjuvant present in the vaccine, which protected it from degradation. It is not yet known whether these HPV DNA fragments played a role in the girl's death.
A 2017 article published in Drug Safety looked at the safety issues associated with HPV vaccination.(57) Data reported in the adverse reaction reporting systems of several countries were analyzed and a relatively large number of reports of headache, dizziness, fatigue and syncope associated with prolonged hospitalization or debilitation were found. While some reports reported Postural Orthostatic Tachycardia Syndrome (POTS), Complex Regional Pain Syndrome (CRPS), or Chronic Fatigue Syndrome (CFS) as diagnoses, the vast majority of reports reported no diagnoses. This study also found significantly more events involving a combination of dizziness and headache with syncope or fatigue following HPV vaccination than adverse reactions from other vaccines. It was also noted that these symptom combinations were first reported in the countries that first approved and recommended HPV vaccination, and that the reported symptoms persisted globally.
Because of these findings, others have questioned whether current drug and vaccine safety monitoring tools can adequately detect and respond to signs that there is a serious problem with a currently marketed product.(58) Additionally, a 2018 study found that only about half of the available clinical trials of HPV vaccines had been completed before the vaccines were approved by the Federal Drug Administration (FDA) and the European Medicines Agency (EMA).(59) The study also found that drugmakers only published the results of about two-thirds of HPV clinical trials, leaving the study authors wondering whether drugmakers were selectively choosing which clinical data to publish.
In December 2017, Slate Magazine ran a cover story about the pre-approval clinical trials of the Gardasil vaccine.(60) This investigative report determined that Merck's pre-approval safety studies "used a convoluted method that made objective assessment and reporting of potential side effects impossible during all but a few weeks of the years-long trial."(61) The article noted that Merck's clinical investigators were allowed to use personal judgment in reporting medical problems as adverse events, essentially allowing the study investigators to decide which symptoms, if any, could be related to the vaccination. The study investigators were also allowed to list new post-vaccination health problems as medical history, not adverse events, and to limit safety follow-up to 14 days after each of the three Gardasil vaccination doses. Slate's investigation identified several women involved in pre-licensure trials of Gardasil who reported post-vaccination chronic illnesses to the study investigators, but their symptoms were never reported by Merck.
In April 2018, the Indian Journal of Medical Ethics published a report suggesting that rising cervical cancer rates in Sweden may be associated with HPV vaccination. Concerned that he might be targeted for questioning the safety or efficacy of a vaccine, the study author chose to publish under an assumed name without first contacting the journal. Initially, the magazine decided to allow publication of the article despite the deception, after determining that the author had the necessary credentials and that he faced a credible threat of harm, stating that "the issues raised are important and discussion of them is in the public interest."(62) However, two weeks later, after receiving "valuable advice from the journal's editorial board and others," the article was retracted.(63) The journal, however, said it "hoped that the possibility of possible harm from vaccinating women previously exposed to HPV would be carefully explored in future studies."(64) Data from Gardasil's pre-approval clinical trials had previously demonstrated an increased incidence of grade 2 and 3 cervical intraepithelial neoplasia (CIN) in women previously infected with the particular vaccine target strain.(65)
According to US federal VAERS data, as of January 31, 2023, 618 deaths have been reported following HPV vaccination.(66) In Italy it is impossible to know this data.
References (click to open)
- CDC. Human Papillomavirus (HPV) Vaccine Safety. Jan. 30, 2018
- FDA. Gardasil – Product insert. Apr. 24, 2015.
- FDA. Cervarix – Product insert. Apr. 25, 2016.
- FDA. Gardasil 9 – Product insert. Feb. 9, 2018.
- Brotherton JML, Gold MS. et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ. 2008 Sep 9; 179(6): 525–533.
- Soldevilla HF, Briones SF, Navarre SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus. 2012 Feb;21(2):158-61
- Gatto M, Agmon-Levin N. et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol. (2013) 32:1301.
- Katoulis AC, Liakou A. et al. Erythema multiforme following vaccination for human papillomavirus. Dermatology 2010; 220: 60-2.
- Sekiguchi K, Yasui N. et al. Two cases of acute disseminated encephalomyelitis following vaccination against human papilloma virus. Internal Med. 2016 Nov 1; 55(21): 3181–3184 .
- Yoneda M. Acute Disseminated Encephalomyelitis Following Immunization with Human Papillomavirus Vaccines. Intern Med. 2016 Nov 1; 55(21): 3077–3078 .
- Wildemann B, Jarius S. et al. ACUTE DISSEMINATED ENCEPHALOMYELITIS FOLLOWING VACCINATION AGAINST HUMAN PAPILLOMA VIRUS. neurology. Jun.16, 2009; 72 (24).
- Fernandez-Fournier M, Diaz de Teran J. et al. Early cervical myelitis after human papilloma virus vaccination. Neurol Neuroimmunol Neuroinflamm. 2014 Sep 11;1(3):e31
- Laino C. 2 ALS Cases May Be Linked to Gardasil Vaccine. WebMD. Oct. 16, 2009
- Chang J, Campagnolo D. et al. Demyelingating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry. 2011 Nov;82(11):1296-8.
- Álvarez-Soria MJ, Hernández-González A, et al. Demyelinating disease and vaccination of the human papillomavirus. Rev. Neurol. 2011 Apr 16; 52 (8): 472-6.
- Sutton I, Lahoria R. et al. CNS demyelination and quadrivalent HPV vaccination. Mult scler. 2009 Jan;15(1):116-9.
- Hu Y, Tornes L, Lopez-Alberola R. Two Cases of Pediatric Multiple Sclerosis after Human Papillomavirus Vaccination (P4.353) neurology. Apr. 10, 2018; 90 (15 Supplements)
- Souayah N, Michas-Martin PA. et al. Guillain–Barré syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006–2009. Vaccine. 2011 Jan 29; 29 (5): 886-9.
- Miranda S, Chaignot C. et al. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2 million young girls in France. Vaccine. 2017 Aug 24; 35 (36): 4761-4768.
- Das A, Chang D. et al. Pancreatitis following human papillomavirus vaccination. Med J Aust. 2008 Aug 4;189(3):178.
- Bizjak M, Bruck O. et al. Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry. Immunol Res. 2017 Feb;65(1):164-167.
- Miranda S, Chaignot C. et al. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2 million young girls in France. Vaccine. 2017 Aug 24; 35 (36): 4761-4768.
- Debeer P, De Munter P. et al. Brachial plexus neuritis following HPV vaccination. Vaccine. 2008 Aug 18; 26 (35): 4417-9.
- Taras JS, King JJ, et al. Brachial neuritis following quadrivalent human papilloma virus (HPV) vaccination. Hand (NY). 2011 Dec; 6(4): 454–456.
- DiMario FJ, Jr, Hajjar M. et al. A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus. J Child Neurol. 2010 Mar;25(3):321-7.
- Menge T, Cree B. et al. Neuromyelitis optica following human papillomavirus vaccination. Neurology. 2012 Jul 17;79(3):285-7.
- McCarthy JE, Filiano J. Opsoclonus myoclonus after human papilloma virus vaccine in a pediatric patient. Parkinsonism Relat Disord. 2009 Dec;15(10):792-4.
- Ogino K, Kishi S, Yoshimura N. Multiple Evanescent White Dot Syndrome after Human Papillomavirus Vaccination. Case Rep. Ophthalmol. 2014 Jan-Apr; 5(1): 38–43.
- Cohen SM. Multiple Evanescent White Dot Syndrome After Vaccination for Human Papilloma Virus and Meningococcus. J Pediatr Ophthalmol Strabismus. 2009 Jun 25.
- Yonee C, Toyoshima M. et al. Association of acute cerebellar ataxia and human papilloma virus vaccination: a case report. Neuropediatrics 2013; 44: 265-7.
- Della Corte C, Carlucci A. et al. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in an 11-year-old girl. Vaccines. 2011 Jun 24;29(29-30):4654-6.
- Cerami C, Corbo M. et al. Autoimmune neuromyotonia following human papilloma virus vaccination. Muscle Nerve. Mar 2013;47(3):466–7.
- Melo Gomes S, Glover M. et al. Vasculitis following HPV immunization. Rheumatology (Oxford). 2013 Mar;52(3):581-2.
- Pugnet G, Ysebaert L. et al. Immune thrombocytopenic purpura following human papillomavirus vaccination. Vaccine. 2009 Jun 8;27(28):3690.
- Bizjak M, Bruck O. et al. Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine. Semin Hematol. 2016 Apr;53 Suppl 1:S48-50.
- Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. Eur. J. Neurol. 2014 21:135-139.
- Tomljenovic L, Colafrancesco S. et al. Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the “Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants” Case Report and Literature Review. J Investig Med High Impact Case Rep. 2014 Jan-Mar; 2(1): 2324709614527812.
- Brinth LS, Pors K. et al. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine. 2015 May 21; 33 (22): 2602-5.
- Richards S, Chalkiadis G. et al. Complex regional pain syndrome following immunization. Arch Dis Child. 2012 Oct;97(10):913-5
- Tomljenovic L, Colafrancesco S. et al. Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the “Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants” Case Report and Literature Review. J Investig Med High Impact Case Rep. 2014 Jan-Mar; 2(1): 2324709614527812.
- Kinoshita T, Abe RT. et al. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med. 2014;53(19):2185-200.
- Martínez-Lavín M, Martínez-Martínez LA, Reyes-Loyola P. et al. HPV vaccination syndrome. A questionnaire-based study. Clin Rheumatol. 2015 Nov;34(11):1981-3.
- Little D, Ward HR. Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. BMJ Case Rep. Sep. 30, 2012.
- Colafrancesco S, Perricone C. et al. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol. 2013 Oct;70(4):309-16
- Little DT, Ward HR. Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice. J Investig Med High Impact Case Rep. 2014 Oct 28;2(4):2324709614556129.
- Gruber N, Shoenfeld Y. A link between human papilloma virus vaccination and primary ovarian insufficiency: current analysis. Curr Opin Obstet Gynecol. 2015 Aug;27(4):265-70.
- DeLong, G. A lowered probability of pregnancy in females in the USA aged 25–29 who received a human papillomavirus vaccine injection. J Toxicol Environ Health A. 2018;81(14):661-674.
- Shoenfeld Y, Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmune. 2011 Feb;36(1):4-8
- Tomljenovic L, Colafrancesco S. et al. Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the “Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants” Case Report and Literature Review. J Investig Med High Impact Case Rep. 2014 Jan-Mar; 2(1): 2324709614527812.
- Colafrancesco S, Perricone C. et al. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol. 2013 Oct;70(4):309-16
- Hotta O, Tanaka A. et al. Involvement of chronic epipharyngitis in autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA). Immunol Res. 2017 Feb;65(1):66-71.
- Poddighe D, Castelli L. et al. A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder? Immunol Res. 2014;60(2–3):236–246.
- Palmieri B, Poddighe D. et al. Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature. Immunol Res. 2017; 65(1): 106–116.
- Pellegrino P, Perrone V. et al. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems. Immunol Res. 2015 Feb;61(1-2):90-6.
- Inbar R, Weiss R. et al. Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil. Immunol Res. 2017 Feb;65(1):136-149
- Tomljenovic L, Shaw CA. Death after Quadrivalent Human Papillomavirus (HPV) Vaccination: Causal or Coincidental? Pharmaceutical Regulatory Affairs: Open Access 2012,S12:001
- Chandler RE, Juhlin K. et al. Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®. Drug Saf. 2017; 40(1): 81–90.
- Chandler RE. Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient? Drug Saf. 2017; 40(12): 1167–1170.
- Jørgensen L, Gøtzsche PC, Jefferson T. et al. Index of the human papillomavirus (HPV) vaccine industry clinical study programs and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. System Rev. 2018; 7:8.
- Joelving F. What the Gardasil Testing May Have Missed. Slate. Dec 17, 2017.
- Ibid
- EDITORIAL NOTE Statement on Corrections. Indian J Med Ethics. May 9, 2018.
- Andersson L. Comment - RETRACTED: Increased incidence of cervical cancer in Sweden: Possible link with HPV vaccination. Indian J Med Ethics. May 26, 2018.
- Ibid
- FDA Center for Biologics Evaluation and Research. Vaccines and Related Biological Products Advisory Committee Meeting. May 18, 2006.
- CDC. Human Papillomavirus (HPV) Vaccine Safety. Jan. 30, 2018
This article is summarized and translated by National Vaccine Information Center.
